Two doses of the mRNA BNT162b2 vaccine reduce severe outcomes, viral load and secondary attack rate: evidence from a SARS-CoV-2 Alpha outbreak in a nursing home, Osnabrueck, Germany, January-March 2021

A SARS-CoV-2 Alpha outbreak was detected in a nursing home after residents and staff had completed vaccination with BNT162b. In a retrospective cohort study, we estimated an age-adjusted vaccine effectiveness of 88% [95% confidence interval (95%CI) 41-98%] against hospitalization/death. Ct values at diagnosis were higher with longer intervals since the second vaccination [>21 vs. [≤]21 days: 4.82 cycles, 95%CI: 0.06-9.58]. Secondary attack rates were 67% lower in households of vaccinated [2/9 (22.2%)] than unvaccinated infected staff [12/18 (66.7%); p=0.046]. Vaccination reduced the risk of severe outcomes, Ct values and transmission, but not fully. Non-pharmaceutical interventions remain important for vaccinated individuals.


33
Text 34 Background 35 While COVID-19 case-fatality was <0.1% in under-50-year-olds [1], it was 13% in outbreaks of  CoV-2 in nursing homes from January 2020 to February 2021 in Germany [2]. Hence, nursing homes 37 were prioritized for COVID-19 vaccination which began in Germany in December 2020 [3]. We report 38 on a SARS-CoV-2 Alpha (B.1.1.7) outbreak among residents and staff of a nursing home in Germany, 39 of whom some were vaccinated with two doses of BNT162b. This study describes the epidemiology 40 of the outbreak, the undertaken control measures and the vaccine effectiveness (VE) against SARS-41 CoV-2 Alpha infections, disease and severe outcomes (hospitalization or death) and the vaccine 42 effects on viral load and secondary transmission. 43 Study design 44 Cases were defined as residents (either permanent or day-care) or staff who had a positive SARS-45 CoV-2-PCR between early January 2021 (symptom onset of first case denoted as day 0) and mid-46 March 2021 (2 weeks after diagnosis of the last case, day 74). In a retrospective cohort study, we 47 included all residents and staff who attended the nursing home during the same time period. We 48 compared attack rates (AR) with Chi-squared or Fisher's exact tests. We estimated vaccine 49 effectiveness (VE) as VE=1-RR, where RR denotes the relative risk for the respective outcome in 50 vaccinated vs. unvaccinated individuals, calculated by Poisson regression. Considered outcomes were 51 SARS-CoV-2 infection, symptomatic infection and severe courses (defined as hospitalization or death 52 from COVID-19). Using linear regression, we analyzed the effect of the time interval between the 53 second vaccine dose and viral load at diagnosis (using Ct value for the ORF1AB gene at the first 54 positive PCR as a proxy). Unvaccinated cases were assigned an interval of 0 days. We assessed 55 secondary attack rates (SAR) among household members of SARS-CoV-2-positive staff, who were 56 tested twice during their quarantine. One household outside the administrative district was excluded 57 because data was unavailable. Secondary cases were defined as SARS-CoV-2 PCR-positive household 58 members diagnosed [1][2][3][4][5][6][7][8][9][10][11][12][13][14]  Measures in place before the outbreak 70 All staff had to conduct daily rapid antigen detection tests (RADT). Residents were tested related to 71 incidences, e.g. when becoming symptomatic. All visitors of the nursing homes could only enter with 72 a negative RADT of the same day. Staff and visitors had to wear FFP2 standard masks inside the 73 nursing home. Staff was assigned in teams to designated wards and rotation between wards was 74 minimized. However, this was not possible for night shifts and social workers. 75 The epidemiology of the outbreak 76 After detecting the first SARS-CoV-2 infection in a permanent care resident in early February 2021 77 (day 30) and previous, sporadic cases among four staff since early January 2021 (day 0), an outbreak 78 investigation was initiated. Between early January 2021 (day 0) and 14 days after the detection of the 79 last case in mid-March 2021 (day 74), 50 SARS-CoV-2 cases were detected, of which 35 were 80 symptomatic (70%; 16/35 (46%) vaccinated). Four residents (1/4 (25%) vaccinated) were hospitalized 81 . CC-BY 4.0 International license It is made available under a perpetuity.
is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted September 23, 2021. ;https://doi.org/10.1101https://doi.org/10. /2021 and five died (2/5 (40%) vaccinated) from or with COVID-19. The crude AR among residents (AR=27%, 82 34/124) was higher than among staff (AR=12%, 16/128, p<0.01). Typing of PCR samples for variants 83 of concern detected variant Alpha in 27/28 samples. 84 The course of the outbreak 85 A kitchen staff, working in a kitchen serving all sections, developed symptoms on day 0, worked for 86 two more days prior to isolation with no reported contacts to other care sections. Between day 8 and 87 day 23, mainly the day-care was affected with nine detected cases (eight residents and one member 88 of staff) and was therefore closed. In the stationary care, two members of staff developed symptoms 89 on day 28 and a resident was RADT-positive on day 30. Subsequently, the outbreak spread in the 90 permanent care wards, see Figure 1 and 2. 91 Potential sources of the outbreak 92 All members of the vaccination team were tested negative with daily RADT and with weekly PCR. 93 Therefore, it seems unlikely that the vaccination team was the source of the outbreak. Initially, no 94 links between the day-care and the stationary care were reported. However, the contact tracing 95 information revealed that an external health-care worker (ID-5160, see Figure 3) visited a highly 96 infectious case (ID-2640, Ct value 11) from the day-care on day 10 and a person from the permanent 97 care (ID-870) on day 12 (who tested positive later), suggesting that they visited ID-870 within the 98 infectious period. ID-5160 was tested positive with an RADT on day 13. Potentially, the ID-5160 99 represents a link between these two sections. However, no sequencing data was available to further 100 delineate possible transmission chains. The other 165 visitors of the nursing home did not have 101 timely relevant SARS-CoV-2 infections and were therefore excluded as potential sources of 102

infections. 103
Outbreak management 104 On day 32, 4 days after the first member of staff of the stationary care was symptomatic, regular PCR 105 serial testing was implemented for all residents and staff every 5 days until two consecutive PCR 106 . CC-BY 4.0 International license It is made available under a perpetuity.
is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted September 23, 2021. ; https://doi.org/10.1101/2021.09.13.21262519 doi: medRxiv preprint serial tests had negative results only. All symptomatic or PCR-positive residents were isolated as a 107 cohort on a designated ward. Non-cases could move within their ward but contacts between wards 108 were minimized. Close contacts were quarantined in their rooms. Case isolation ended once cases 109 were asymptomatic and were PCR-negative at the earliest after 14 days. No visitors were allowed 110 between day 31 and day 74. 111 Vaccine effectiveness 112 Among 29 vaccinated cases, the date of diagnosis (defined as the earlier date of either symptom-113 onset or sampling of a positive test) was 7-11 days after the second vaccine in 14 cases (48%, all 114 residents), while 15 (52%) were diagnosed 20 or more days post vaccination. SARS-CoV-2 infections 115 were diagnosed less frequently among vaccinated than unvaccinated residents ( p<0.01) against disease. Of 50 cases, four were hospitalized (1/4 (25%) vaccinated) and five (2/5 120 (40%) vaccinated) died (all residents). Age-adjusted VE ≥7 days after completed vaccination was 88% 121 (37-98%; p=0.01) against severe outcomes. 122 Age confounded the association between vaccination status and infection, disease and severe 123 outcomes, changing effect estimates by 21% (from 0.70 to 0.55), 20% (from 0.40 to 0.32) and 50% 124 (from 0.24 to 0.12), respectively (Table 2). Gender was not associated with risks for infection (p=0.64) 125 or disease (p=0.69), but women exhibited a lower risk for severe outcomes (p=0.07, is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint Ct values at diagnosis were on average 3.04 cycles (Table 3, p=0.28) higher among vaccinated than 132 unvaccinated cases. The Ct value increased with time since the second vaccine dose (Table 3 and 133 Figure 3). Age (p=0.79) and sex (p=0.61) was not associated with the Ct value (Table 3). 134 Vaccination reduced secondary transmission in households 135 We analyzed 14 households of SARS-CoV-2-positive staff (five vaccinated, nine unvaccinated). We 136 found two secondary cases in 1/5 (20%) households of vaccinated staff (index staff case was 137 diagnosed 25 days after the second vaccination) and 12 secondary cases in 5/9 (56%) households of 138 infected, unvaccinated staff. For calculating the adjusted SAR, we excluded household members with 139 a PCR-confirmed SARS-CoV-2 infection <6 months prior or who quarantined separately from infected 140 staff. Household members with a vaccinated index case had a lower SAR [2/9 (22%)] than household 141 members of unvaccinated SARS-CoV-2-positive staff (p=0.046, Fisher's exact test, Table 4). 142 Discussion 143 In our study, the age-adjusted VE of two doses of BNT162b was moderate against infection and 144 disease and high against severe COVID-19. Our VE estimates are lower than in a population-based 145 cohort study conducted in Israel [4] that reported a VE of 96% against hospitalization and 93% 146 against death. This can be explained by a higher potential for repeated contacts with infected cases 147 and a higher median age in this outbreak setting. Furthermore, half of the vaccinated cases were 148 diagnosed within 7-11 days after the second vaccination; thus, infection occurred prior to attaining 149 full immunity. However, we did not observe higher effectiveness among cases with a longer interval 150 between the second vaccine and diagnosis, in line with findings from the UK is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint We believe that the regular PCR serial testing, isolating cases on a designated ward and quarantining 172 close contacts of cases in their rooms contributed to the successful outbreak control. It is possible 173 that the outbreak on the day-care and the stationary ward were linked via a visiting health-care 174 worker. However, typing revealed that at least two different strains were present in this outbreak, 175 suggesting two introductory events of SARS-CoV-2 at minimum. 176

177
Two doses of BNT162b significantly reduced the risk for SARS-CoV-2 infections, symptomatic 178 infections, severe outcomes, viral load and secondary transmission, even within 14 days after the 179 second dose. However, the incomplete protection emphasizes that adhering to non-pharmaceutical 180 . CC-BY 4.0 International license It is made available under a perpetuity.
is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint  is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint  is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted September 23, 2021. Tables   244   245   Table 1 is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

: Outcomes of a SARS-CoV-2 Alpha outbreak in a nursing home in Germany, Jan-Mar 2021, stratified by
The copyright holder for this this version posted September 23, 2021. ;https://doi.org/10.1101https://doi.org/10. /2021  is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted September 23, 2021. ;https://doi.org/10.1101https://doi.org/10. /2021  is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint  is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint  is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted September 23, 2021. ; https://doi.org/10.1101/2021.09.13.21262519 doi: medRxiv preprint

Figure 2: Cases of SARS-CoV-2 Alpha by time of diagnosis during an outbreak in a nursing home in 275
Germany, Jan-Mar 2021 276 Color represents the area of residence or activity within the nursing home ("all" if no designation to a 277 specific ward is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted September 23, 2021. ; https://doi.org/10.1101/2021.09.13.21262519 doi: medRxiv preprint  is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted September 23, 2021. ; https://doi.org/10.1101/2021.09.13.21262519 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted September 23, 2021. ; https://doi.org/10.1101/2021.09.13.21262519 doi: medRxiv preprint